References
- Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): pre-clinical profile and comparison with other agents that selectively inhibit cyclooxygensase-2. J Pharmacol Exp Ther 2001;296:558–66
- Tacconelli S. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. Curr Med Res Opin 2002;18:503–11
- Patrignani P, Capone ML, Tacconelli S. Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Exp Opin Pharmacother 2003;4: 265–84
- Hunt RH, Harper S, Callegari P, et al. Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib. Aliment Pharmacol Ther 2003;17:201–10
- Matsumoto AK, Melian A, Mandel DR, et al. for the Etoricoxib Rheumatoid Arthritis Study Group. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 2002;29:1623–30
- Leung AT, Malmstrom K, Gallacher AE, et al. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: a randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial. Curr Med Res Opin 2002;18:49–58
- Collantes E, Curtis SP, Lee KW, et al. A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis (ISRCTN25142273). BMC Family Practice 2002;3:10
- Gottesdiener K, Schnitzer T, Fisher C, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis Rheumatology 2002;41:1052–61
- Schumacher Jr. HR, Boice JA, Daikh DI, J et al. Randomised double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. Br Med J 2002;324:1488–92
- Cochrane DJ, Jarvis B, Keating GM. Etoricoxib – Adis new drug profile. Drugs 2002; 62: 2637–51
- Melian A, Van der Heijde D, James M, et al. Etoricoxib in the treatment of ankylosing spondylitis (AS) [poster presentation]. American Congress of Rheumatology, New Orleans, US, 2002
- Steinfeld S, Poriau S. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of the EVA (Experience with VIOXX in Arthritis) Survey. Curr Med Res Opin 2001;17:1–7
- Zacher J, Schattenkirchner M. Patient and physician satisfaction with rofecoxib in osteoarthritis: results of a post-marketing surveillance study in primary care in Germany. Curr Med Res Opin 2002;18:229–36
- Ware JE, Kosinski M, Dewey JE, Gandek B. How to score and interpret single-item health status measures: a manual for users of the SF-8™ Health Survey. Lincoln, RI: QualityMetric Incorporated; 2001
- Rabin R, de Charo F. EQ-5D: a measure of health status from the EuroQoL group. Ann Med 2001;33:337–43
- The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. Health Policy 1990;16(3):199–208
- Bellamy, N. WOMAC osteoarthritis index: a user’s guide. 1995
- Bellamy N, et al. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to anti-rheumatic drug therapy in patients with osteoarthritis of the hip or knee. J Rheumatol 1988; 15:1833–40
- Hunsche E, Geling O, Kong SX, Watson DJ, Noble I. Daily activities of osteoarthritis patients on etoricoxib versus naproxen [poster presentation]. Sydney, Australia: OARSI; 2002
- Melian A, Zhao, P-L, Curtis S, Watson DJ, Hunsche E. Improved quality of life (QoL) with etoricoxib compared with placebo in patients with rheumatoid arthritis (RA) [poster presentation]. Stockholm, Sweden: EULAR; 2002